Literature DB >> 3973008

Biosynthesis of factor V in isolated guinea pig megakaryocytes.

H C Chiu, P K Schick, R W Colman.   

Abstract

Although platelets contain Factor V, localized primarily in the alpha-granules, the origin of this coagulation cofactor in these cells is not known. We therefore explored whether isolated megakaryocytes could biosynthesize Factor V. Guinea pig plasma Factor V coagulant activity was demonstrated to be neutralized by human monoclonal and rabbit polyclonal antibodies directed monospecifically against human Factor V. These antibodies had been used earlier to purify human Factor V. These antibodies had been used earlier to purify human Factor V and to quantify Factor V antigen concentration, respectively (1983. Chiu, H. C., E. Whitaker, and R. W. Colman. J. Clin. Invest. 72:493-503). As determined by a competitive enzyme-linked immunosorbent assay with guinea pig plasma as a standard, Factor V solubilized from guinea pig megakaryocytes was present at 0.098 +/- 0.018 micrograms/10(5) cells. Each megakaryocyte contained about 500 times as much Factor V as is in a platelet (0.234 +/- 0.180 micrograms/10(8) platelets). The content of Factor V antigen in guinea pig plasma was greater (27.0 +/- 3.0 micrograms/ml) than that of Factor V antigen in human plasma (11.1 +/- 0.4 micrograms/ml). In contrast, human platelets contain ninefold more Factor V antigen (2.01 +/- 1.09 micrograms/10(8) platelets) than do guinea pig were 2.85 +/- 0.30 U/ml plasma, 0.022 +/- 0.012 U/10(8) platelets, and 0.032 +/- 0.03 U/10(5) megakaryocytes, compared with human values of 0.98 +/- 0.02 U/ml plasma and 0.124 +/- 0.064 U/10(8) platelets. Isolated megakaryocytes were found to contain Factor V by cytoimmunofluorescence. The megakaryocytes were incubated with [35S]methionine, and radiolabeled intracellular proteins purified were on a human anti-Factor V immunoaffinity column. The purified protein exhibited Factor V coagulant activity and neutralized the inhibitory activity of a rabbit antihuman Factor V antibody, which suggests that megakaryocyte Factor V is functionally and antigenically intact. These results indicate that Factor V is synthesized by guinea pig megakaryocytes. Nonetheless, megakaryocyte Factor V was more slowly activated by thrombin and in the absence of calcium was more stable after activation than was plasma Factor Va. Electrophoresis in sodium dodecyl sulfate and autoradiography of the purified molecule showed a major band of Mr 380,000 and a minor band of Mr 350,000, as compared with guinea pig and human plasma Factor V, where the protein had an Mr of 350,000. Both forms of Factor V were substrates for thrombin. Possible explanations for the higher molecular weight and different thrombin sensitivity and stability observed are that a precursor of Factor V was isolated or that the megakaryocyte Factor V had not been fully processed before isolation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3973008      PMCID: PMC423488          DOI: 10.1172/JCI111706

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  The Function of Ac-Globulin in Blood Clotting.

Authors:  A G Ware; R C Murphy; W H Seegers
Journal:  Science       Date:  1947-12-19       Impact factor: 47.728

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  The interaction of human coagulation factor Va with platelets.

Authors:  W H Kane; P W Majerus
Journal:  J Biol Chem       Date:  1982-04-10       Impact factor: 5.157

4.  Immunochemical studies of factor V of bovine platelets.

Authors:  T R Ittyerah; R Rawala; R W Colman
Journal:  Eur J Biochem       Date:  1981-11

5.  Demonstration of factor XIII in human megakaryocytes by a fluorescent antibody technique.

Authors:  T H Kiesselbach; R H Wagner
Journal:  Ann N Y Acad Sci       Date:  1972-12-08       Impact factor: 5.691

6.  Synthesis of actin by cultured guinea pig megakaryocytes. Complex formation with fibrin.

Authors:  R Nachman; R Levine; E Jaffe
Journal:  Biochim Biophys Acta       Date:  1978-09-21

7.  Properties of the factor Xa binding site on human platelets.

Authors:  J P Miletich; C M Jackson; P W Majerus
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

8.  Factor V binding to human platelets: the role of divalent cations and of platelet preparatory methods.

Authors:  T R Ittyerah; R Rawala; R W Colman
Journal:  Thromb Res       Date:  1982-04-01       Impact factor: 3.944

9.  Cholesterol and phospholipid biosynthesis in guinea pig megakaryocytes.

Authors:  B P Schick; P K Schick
Journal:  Biochim Biophys Acta       Date:  1981-01-26

10.  New synthesis of a platelet-specific protein: platelet factor 4 synthesis in a megakaryocyte-enriched rabbit bone marrow culture system.

Authors:  R Ryo; A Nakeff; S S Huang; M Ginsberg; T F Deuel
Journal:  J Cell Biol       Date:  1983-02       Impact factor: 10.539

View more
  8 in total

1.  Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin.

Authors:  W H Kane; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

2.  Incorporation of a circulating protein into megakaryocyte and platelet granules.

Authors:  P J Handagama; J N George; M A Shuman; R P McEver; D F Bainton
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

3.  Immunoglobulin G is a platelet alpha granule-secreted protein.

Authors:  J N George; S Saucerman; S P Levine; L K Knieriem; D F Bainton
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

4.  Incorporation of intravenously injected albumin, immunoglobulin G, and fibrinogen in guinea pig megakaryocyte granules.

Authors:  P J Handagama; M A Shuman; D F Bainton
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

5.  Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation.

Authors:  Mettine H A Bos; Rodney M Camire
Journal:  J Coagul Disord       Date:  2010-07-01

6.  Role of hepatocyte nuclear factor 4alpha in control of blood coagulation factor gene expression.

Authors:  Yusuke Inoue; Luanne L Peters; Sun Hee Yim; Junko Inoue; Frank J Gonzalez
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

Review 7.  The molecular basis of factor V and VIII procofactor activation.

Authors:  R M Camire; M H A Bos
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

8.  Report of a rare co-incidence of congenital factor V deficiency and thalassemia intermedia in a family.

Authors:  Yasser Abou Mourad; Ali Shamseddine; Ayad Hamdan; Susane Koussa; Ali Taher
Journal:  Ann Saudi Med       Date:  2004 Jul-Aug       Impact factor: 1.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.